Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1352
Shown on this page
12
Current sort
Recently updated
Location scope
New Haven, CT
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within New Haven, Connecticut. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 601–612 of 1,352 matching trials in New Haven, CT.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults

NCT06821750
View directory record Official record
Conditions
Healthy
Interventions
PF-07314470, Placebo for PF-07314470
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Completed Phase 3 Interventional Results available

Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation

NCT03683030
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Multi-Electrode RF Balloon Catheter
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

NCT04496518
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Intrinsic Antitachycardia Pacing (iATP) Therapy
Device
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Active, not recruiting No phase listed Observational

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

NCT04489225
View directory record Official record
Conditions
Heart Failure
Interventions
Observational
Other
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Active, not recruiting No phase listed Observational

IN.PACT™ AV Access Post-Approval Study (PAS002)

NCT04543539
View directory record Official record
Conditions
Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
Interventions
IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
Combination Product
Lead sponsor
Medtronic
Industry
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Active, not recruiting No phase listed Observational

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

NCT04710563
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Completed Not applicable Interventional Results available

Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes

NCT04955691
View directory record Official record
Conditions
Type1diabetes, Low Carbohydrate Diet
Interventions
low carbohydrate diet, standard carbohydrate diet
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Completed Phase 3 Interventional Results available

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Completed Not applicable Interventional Results available

Learning Alerts for Acute Kidney Injury

NCT02786277
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Alert
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Completed Not applicable Interventional

Tka Assay for CDK4/6i

NCT06572800
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Interventions
DiviTum-TKa
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Nov 15, 2026, 2:29 PM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 15, 2026, 2:29 PM EST